RAP
vs
S&P/ASX 300

Over the past 12 months, RAP has underperformed S&P/ASX 300, delivering a return of 0% compared to the S&P/ASX 300's 10% growth.
Stocks Performance
RAP vs S&P/ASX 300
Performance Gap
RAP vs S&P/ASX 300
Performance By Year
RAP vs S&P/ASX 300
Resapp Health Ltd
Glance View
ResApp Health Ltd. engages in the research and commercial development of ResApp technology for the purpose of providing health care solutions for respiratory disease. The company is headquartered in Brisbane, Queensland. The company went IPO on 2005-01-12. The Company’s digital healthcare solutions assists doctors and patients to diagnose and manage respiratory disease. The firm has developed a platform for diagnosing respiratory disease using the sound of a patient’s cough. The platform is based on sound alone and does not require physical contact with the patient. With smartphones integrating microphones, the platform can be delivered without the need for additional hardware. The firm has developed smartphone-based machine learning algorithms, which can identify exacerbations in patients with asthma or COPD. The company also has ongoing clinical programs investigating the use of these techniques to measure exacerbation severity and lung function. The firm has developed an obstructive sleep aponia screening test that uses overnight breathing and snoring sounds recorded on a smartphone placed on the bedside table.
